Belinostat

贝林司他

Report date: 2025/02/12 11:39:11
NME

Base Information

Drug NameBelinostat
Drug Alias NameComboBelCHOP贝利司他贝诺司他belinostatumBeleodaq +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHistone deacetylase inhibitors
TargetsHistone deacetylase
Therapy Area/IndicationsSolid tumoursAngioimmunoblastic T-cell LymphomaCentral Nervous System Lymphoma +[58] 
Global Approved IndicationsLymphoma, T-Cell, Peripheral
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2014/07/03
Country/TerritoryBelgiumCanadaUnited States +[22] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesCuragen Corporation
China Registration ClassN/A

Develop Information

Active CompaniesTopotarget ASSpectrum Pharmaceuticals IncEmory University +[6] 
Inactive CompaniesUtah State UniversityAcrotech Biopharma IncHoly Cross Hospital Inc +[8] 
Active IndicationsGlioblastomaLymphoma, T-Cell, PeripheralLymphoma, T-Cell
Inactive IndicationsSolid tumoursAngioimmunoblastic T-cell LymphomaCentral Nervous System Lymphoma +[55] 

Other Information

ATC CodeL01XH04
Related LinksWikipediaDrugBankKEGG